clinicaltrialsarena

Veradermics’ stock up on male hair loss trial success

The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...
clinicaltrialsarena

Merz concludes enrolment in Phase III Xeomin trials for migraine

Migraine involves recurrent attacks of moderate to severe head pain, frequently accompanied by sensitivity to light and sound. Credit: Tunatura/Shutterstock.com. Merz Therapeutics has concluded ...
clinicaltrialsarena

Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...
clinicaltrialsarena

Vanda puts anxiety drug’s development on ice after Phase III fail

Vanda has put the late-stage programme for VQW-765 in SAD on ice at it assesses the full dataset. Credit: omahgrafisgk / Shutterstock.com. Vanda Pharmaceuticals has hit pause on a late-stage programme ...
clinicaltrialsarena

Pilatus doses first patient in Phase I PLT012 trial for HCC

The trial intends to use the clinical findings to guide the future development of PLT012 across liver disease. Credit: Shidlovski/Shutterstock.com. Pilatus Biosciences has dosed the first patient in ...
clinicaltrialsarena

AstraZeneca pins bone disease drug’s Phase III failure on high placebo response

Efzimfotase alfa offered numerical, but not statistically significant improvements in patient six-minute walk test values in the HICKORY trial in hypophosphatasia. Credit: Lemberg Vector studio / ...
clinicaltrialsarena

Lilly reports Phase IIIb data on Taltz and Zepbound combination

The trial randomised 274 participants to subcutaneous Taltz or the combination, alongside counselling on diet and physical activity. Credit: Pixel-Shot/Shutterstock.com. Eli Lilly and Company has ...
clinicaltrialsarena

Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033

A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
clinicaltrialsarena

J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win

Johnson & Johnson said there is a second pivotal trial of Caplyta in bipolar I. Credit: josefkubes / Shutterstock..com Johnson & Johnson’s (J&J’s) $14.6bn acquisition of Intra-Cellular Therapies is ...
clinicaltrialsarena

Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint

The trial enrolled 248 adults aged 18 to 70 with moderate-to-severe SLE. Credit: Jarun Ontakrai / Shutterstock.com. Beeline Medicines has announced that its global Phase II clinical trial involving ...
clinicaltrialsarena

Alumis’ lupus drug heads to Phase III despite mid-stage miss

Alumis will progress envudeucitinib to Phase III in SLE, despite the study miss across the general population. Credit: StanislavSukhin / Shutterstock.com. California-based biopharma company Alumis is ...
clinicaltrialsarena

Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data

Bausch + Lomb has chosen to advance two of its pharmaceutical assets further down the clinical pipeline, despite one of the drugs posting mixed data. The first therapy the Canadian company will ...